FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046760717> ?p ?o ?g. }

• W2046760717 endingPage "e150" @default.
• W2046760717 startingPage "e137" @default.
• W2046760717 abstract "Introduction Co-trimoxazole prophylaxis is used to reduce morbidity and mortality in people with HIV. We systematically reviewed three topics related to co-trimoxazole prophylaxis to update WHO guidelines: initiation, discontinuation, and dose. Methods We searched PubMed, Embase, WHO Global Index Medicus, and clinical trial registries in November, 2013, for randomised controlled trials and observational studies including co-trimoxazole prophylaxis and a comparator group. Studies were eligible if they reported death, WHO clinical stage 3 or 4 events, admittance to hospital, severe bacterial infections, tuberculosis, pneumonia, diarrhoea, malaria, or treatment-limiting adverse events. Infant mortality, low birthweight, and placental malaria were additional outcomes for the comparison of co-trimoxazole prophylaxis and intermittent preventive treatment for malaria in pregnant women (IPTp). We compared a dose of 480 mg co-trimoxazole once a day with one of 960 mg co-trimoxazole once a day. We used a 10% margin for non-inferiority and equivalence analyses. We used random-effects models for all meta-analyses. This study is registered with PROSPERO, number CRD42014007163. Findings 19 articles, published from 1995 to 2014 and including 35 328 participants, met the inclusion criteria. Co-trimoxazole prophylaxis reduced rates of death (hazard ratio [HR] 0·40, 95% CI 0·26–0·64) when started at CD4 counts of 350 cells per μL or lower with antiretroviral therapy (ART) worldwide. Co-trimoxazole prophylaxis started at higher than 350 cells per μL without ART reduced rates of death (0·50, 0·30–0·83) and malaria (0·25, 0·10–0·57) in Africa. Co-trimoxazole prophylaxis was non-inferior to IPTp with respect to infant mortality (risk difference [RD] −0·05, 95% CI −0·12 to 0·02), low birthweight (0·00, −0·07 to 0·07), and placental malaria (0·00, −0·10 to 0·10). Co-trimoxazole prophylaxis continuation after ART-induced recovery with CD4 counts higher than 350 cells per μL reduced admittances to hospital (HR 0·42, 95% CI 0·22–0·80), pneumonia (0·73, 0·61–0·88), malaria (0·03, 0·01–0·10), and diarrhoea (0·61, 0·48–0·78) in Africa. A dose of 480 mg co-trimoxazole prophylaxis once a day did not reduce treatment-limiting adverse events compared with 960 mg once a day (RD −0·07, 95% CI −0·52 to 0·39). Interpretation Co-trimoxazole prophylaxis should be given with ART in people with CD4 counts of 350 cells per μL or lower in low-income and middle-income countries. Co-trimoxazole prophylaxis should be provided irrespective of CD4 count in settings with a high burden of infectious diseases. Pregnant women with HIV in Africa should use co-trimoxazole rather than IPTp to prevent malaria complications in infants. Further research is needed to inform dose optimisation and co-trimoxazole use in the context of expanded ART in different epidemiological settings. Funding None." @default.
• W2046760717 created "2016-06-24" @default.
• W2046760717 creator A5004047139 @default.
• W2046760717 creator A5023527880 @default.
• W2046760717 creator A5024120430 @default.
• W2046760717 creator A5028339815 @default.
• W2046760717 creator A5030685765 @default.
• W2046760717 creator A5039024336 @default.
• W2046760717 creator A5061654869 @default.
• W2046760717 creator A5067439986 @default.
• W2046760717 date "2015-04-01" @default.
• W2046760717 modified "2023-09-30" @default.
• W2046760717 title "Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis" @default.
• W2046760717 cites W1539475119 @default.
• W2046760717 cites W1963733265 @default.
• W2046760717 cites W1964748194 @default.
• W2046760717 cites W1972305066 @default.
• W2046760717 cites W1975950064 @default.
• W2046760717 cites W1996893856 @default.
• W2046760717 cites W2007010240 @default.
• W2046760717 cites W2007239126 @default.
• W2046760717 cites W2012477550 @default.
• W2046760717 cites W2013627465 @default.
• W2046760717 cites W2027563386 @default.
• W2046760717 cites W2037073363 @default.
• W2046760717 cites W2040282709 @default.
• W2046760717 cites W2042109679 @default.
• W2046760717 cites W2042271008 @default.
• W2046760717 cites W2047996518 @default.
• W2046760717 cites W2052409578 @default.
• W2046760717 cites W2053638646 @default.
• W2046760717 cites W2056440737 @default.
• W2046760717 cites W2057488914 @default.
• W2046760717 cites W2060831367 @default.
• W2046760717 cites W2078730332 @default.
• W2046760717 cites W2081757964 @default.
• W2046760717 cites W2098793037 @default.
• W2046760717 cites W2100106336 @default.
• W2046760717 cites W2100382099 @default.
• W2046760717 cites W2107328434 @default.
• W2046760717 cites W2109291694 @default.
• W2046760717 cites W2110779038 @default.
• W2046760717 cites W2111278397 @default.
• W2046760717 cites W2111868164 @default.
• W2046760717 cites W2116363030 @default.
• W2046760717 cites W2119264739 @default.
• W2046760717 cites W2119389667 @default.
• W2046760717 cites W2120589103 @default.
• W2046760717 cites W2123725349 @default.
• W2046760717 cites W2125404477 @default.
• W2046760717 cites W2125435699 @default.
• W2046760717 cites W2126930838 @default.
• W2046760717 cites W2128076015 @default.
• W2046760717 cites W2130060580 @default.
• W2046760717 cites W2131406035 @default.
• W2046760717 cites W2135697062 @default.
• W2046760717 cites W2140369030 @default.
• W2046760717 cites W2142064497 @default.
• W2046760717 cites W2142231942 @default.
• W2046760717 cites W2148976672 @default.
• W2046760717 cites W2149864291 @default.
• W2046760717 cites W2150730044 @default.
• W2046760717 cites W2151145423 @default.
• W2046760717 cites W2157823046 @default.
• W2046760717 cites W2159324987 @default.
• W2046760717 cites W2159620379 @default.
• W2046760717 cites W2163672747 @default.
• W2046760717 cites W2165338002 @default.
• W2046760717 cites W2165394545 @default.
• W2046760717 cites W2170719678 @default.
• W2046760717 cites W2186657631 @default.
• W2046760717 cites W2315684369 @default.
• W2046760717 cites W2324241651 @default.
• W2046760717 cites W3022903699 @default.
• W2046760717 cites W4246724847 @default.
• W2046760717 cites W2045411665 @default.
• W2046760717 doi "https://doi.org/10.1016/s2352-3018(15)00005-3" @default.
• W2046760717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26424674" @default.
• W2046760717 hasPublicationYear "2015" @default.
• W2046760717 type Work @default.
• W2046760717 sameAs 2046760717 @default.
• W2046760717 citedByCount "59" @default.
• W2046760717 countsByYear W20467607172015 @default.
• W2046760717 countsByYear W20467607172016 @default.
• W2046760717 countsByYear W20467607172017 @default.
• W2046760717 countsByYear W20467607172018 @default.
• W2046760717 countsByYear W20467607172019 @default.
• W2046760717 countsByYear W20467607172020 @default.
• W2046760717 countsByYear W20467607172021 @default.
• W2046760717 countsByYear W20467607172022 @default.
• W2046760717 countsByYear W20467607172023 @default.
• W2046760717 crossrefType "journal-article" @default.
• W2046760717 hasAuthorship W2046760717A5004047139 @default.
• W2046760717 hasAuthorship W2046760717A5023527880 @default.
• W2046760717 hasAuthorship W2046760717A5024120430 @default.
• W2046760717 hasAuthorship W2046760717A5028339815 @default.
• W2046760717 hasAuthorship W2046760717A5030685765 @default.
• W2046760717 hasAuthorship W2046760717A5039024336 @default.

• next